Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01494662 : HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Patients (men or women) must have histologically or cytologically confirmed invasive
breast cancer, with metastatic disease. Patients without pathologic or cytologic
confirmation of metastatic disease should have unequivocal evidence of metastasis by
physical exam or radiologic study.

- Invasive primary tumor or metastatic tissue confirmation of HER2-positive status

- Over-expression by immunohistochemistry (IHC) with score of 3+ (in > 30% of invasive
tumor cells) AND/OR HER2 gene amplification (> 6 HER2 gene copies per nucleus or a
FISH ratio [HER2 gene copies to chromosome 17 signals] of ? 2.0)

- Note: Patients with a negative or equivocal overall result (FISH ratio of < 2.0 or ?
6.0 HER2 gene copies per nucleus) and IHC staining scores of 0, 1+, 2+ are not
eligible for enrollment

- No increase in corticosteroid dose in the week prior to baseline brain MRI

- Prior trastuzumab and lapatinib therapy are allowed.

- There is no limit to the number of previous lines of therapy (including chemotherapy,
trastuzumab, and endocrine therapies)

- No prior therapy with neratinib is allowed

- At least 2 weeks washout period post chemotherapy, any prior protocol therapy,
lapatinib, other targeted or biologic therapy, or radiation therapy is required prior
to study entry

- No washout is required for hormonal therapy but concurrent hormonal therapy is not
allowed for patients on study

Patients with progressive disease (Cohort 1):

- For cohort 1, patients must have new or progressive CNS lesions, as assessed by the
patient's treating physician.

- In cohort 1, patients must have measurable CNS disease, defined as at least one
parenchymal brain lesion that can be accurately measured in at least one dimension
with longest dimension ?10 mm by local radiology review. Note: measurable non-CNS
disease is NOT required for study participation

- It is anticipated that some patients may have multiple progressive CNS lesions, one
or several of which are treated with SRS or surgery with residual untreated lesions
remaining. Such patients are eligible for enrollment on this study providing that at
least one residual (i.e. non-SRS-treated or non-resected) lesion is measurable (?10

- Patients who have had prior cranial surgery are eligible, provided that there is
evidence of measurable residual or progressive lesions, and at least 2 weeks have
passed since surgery. If a patient has surgical resection followed by WBRT, then
there must be evidence of progressive CNS disease after the completion of WBRT.

- Patients who have had prior WBRT and/or SRS and then whose prior treated lesions have
progressed thereafter are also eligible. In this case, lesions which have been
treated with SRS may be considered as target lesions if there is unequivocal
evidence, in the opinion of the treating physician, of progression.

Patients with with operable disease (Cohort 2):

- In cohort 2, eligible patients will include those who have CNS disease that is
amenable for surgery (typically < 3 brain metastases and with planned resection by
neurosurgery). These patients may include those who have received or not received
previous treatment(s) for their CNS.

- It is anticipated that that patients who have intracranial disease amenable to
surgery will have measurable CNS disease prior to study entry and to resection.
However, this is not an eligibility requirement. Measurable disease is also not
required to continue on protocol subsequent to surgical resection.

- For patients who undergo surgery, postoperative whole brain radiation therapy will
not be allowed while patients are on study (concurrent neratinib and radiation
therapy has not been studied and toxicity of this is unknown). Patients will require
discontinuation of neratinib if radiation therapy will be administered.

Patient Cohort 3:

-In cohort 3, eligible patients must have measurable Central Nervous System disease.
Cohort 3a will have participants with no prior lapatinib therapy. Cohort 3b will have had
prior lapatinib therapy.

Exclusion Criteria:

- Not pregnant or breastfeeding

- Participants who have had chemotherapy or radiotherapy (including investigational
agents) within 2 weeks prior to entering the study or those who have not recovered
adequately from adverse events due to agents administered more than 4 weeks earlier
(excluding alopecia). Washout from trastuzumab is not required.

- Participants who are currently receiving any other investigational agents

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to neratinib

- Concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), including phenytoin,
carbamazepine, oxcarbazepine, fosphenytoin, phenobarbital, pentobarbital, or

- Patients who are receiving any cancer-directed concurrent therapy, such as concurrent
chemotherapy, radiotherapy, or hormonal therapy while on study. Concurrent treatment
with bisphosphonates is allowed but should be started before the first dose of

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- More than two seizures over the last 4 weeks prior to study entry

- Patients with known contraindication to MRI, such as cardiac pacemaker, shrapnel, or
ocular foreign body

- Those with leptomeningeal metastases as the only site of CNS disease

- Significant malabsorption syndrome or inability to tolerate oral medications

- Any predisposing chronic condition resulting in baseline grade 2 or higher diarrhea
LinksPermanent Link to THIS page:      |      Link to official listing
San Francisco, California
Facility: University of California, San Francisco Medical Center
Investigator: Michelle Melisko, MD
Contact: Amy DeLuca Phone: 415-353-7288
Click HERE to send email to this center

Washington, District of Columbia
Facility: MedStar Georgetown Univeristy Hospital
Investigator: Paula R Pohlmann, MD
Contact: Phone: 866-745-2633
Email not avaialable

Baltimore, Maryland
Facility: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Investigator: Roisin Connolly, MD
Contact: Clinical Trials Line Phone: 410-955-8804
Email not avaialable

Boston, Massachusetts
Facility: Dana-Farber Cancer Institute
Investigator: Rachel Freedman, MD, MPH
Contact: Elizabeth Lawler, B.S. Phone: 617-632-5928
Click HERE to send email to this center

Boston, Massachusetts
Facility: Massachusetts General Hosptial
Investigator: Beverly Moy, MD
Contact: Meghan Miles Phone: 617-726-1070
Click HERE to send email to this center

Ann Arbor, Michigan
Facility: University of Michigan Comprehensive Cancer Center
Investigator: Cathy VanPoznak, MD
Contact: Phone: 800-865-1125
Email not avaialable

Chapel Hill, North Carolina
Facility: University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center
Investigator: Carey Anders, MD
Contact: Pete McIlwaine Phone: 919-609-0915
Click HERE to send email to this center

Durham, North Carolina
Facility: Duke University Medical Center
Investigator: Kimberly Blackwell, MD
Contact: Kimberly Riley Phone: 919-660-1278
Click HERE to send email to this center

Pittsburgh, Pennsylvania
Facility: UPMC Cancer Centers - Magee-Womens Hospital of UPMC
Investigator: Shannon Puhalla, MD
Contact: Brenda Lee Steele, RN Phone: 412-641-2261
Click HERE to send email to this center

Houston, Texas
Facility: Baylor College of Medicine Lester and Sue Smith Breast Center
Investigator: Polly Niravath, MD
Contact: Anne C Pavlick Phone: 713-798-7814
Click HERE to send email to this center

Houston, Texas
Facility: MD Anderson Cancer Center
Investigator: Nuhad Ibrahim, MD
Contact: Aurora G Madrigal Phone: 713-745-3888
Click HERE to send email to this center

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557

Website Design By
World Wide Websites